Supplementary Materials

Supplementary Material for:

Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemia

Zainul S. Hasanali, Bikramajit Singh Saroya, August Stuart, Sara Shimko, Juanita Evans, Mithun Vinod Shah, Kamal Sharma, Violetta V. Leshchenko, Samir Parekh, Thomas P. Loughran Jr.,* Elliot M. Epner*

*Corresponding author. E-mail: tploughran{at}virginia.edu (T.P.L.); epner5{at}msn.com (E.E.)

Published 24 June 2015, Sci. Transl. Med. 7, 293ra102 (2015)
DOI: 10.1126/scitranslmed.aaa5079

This PDF file includes:

  • Supplemental patient case information
  • Fig. S1. Cladribine inhibits DNA methylation in vivo and histone methylation in vitro.
  • Fig. S2. Epigenetic therapy does not induce apoptosis in T-PLL.
  • Fig. S3. Epigenetic therapy lowered leukemic white blood cell counts despite multiple relapses.
  • Fig. S4. CD52 expression was unchanged by epigenetic therapy.
  • Fig. S5. CD30 induction was not observed in circulating MCL cells.
  • Fig. S6. Skin biopsy from patient 5 shows CD52-positive dermis-infiltrating lymphocytes.
  • Fig. S7. Epigenetic treatment of T-PLL causes mRNA expression changes in the HIN-200, CEBP, and tribbles families.
  • Fig. S8. All tested patients showed CDKN1B haploinsufficiency, and four of six were TCL1-positive.
  • Fig. S9. Forty percent of patients were positive for the N642H STAT5B mutation.
  • Table S1. Patient presentation at diagnosis.
  • Table S2. Patient characteristics and adverse events.
  • Table S3. Primer sequences.
  • Table S4. Significant P values for all statistically significant comparisons in figures.
  • References (61, 62)

[Download PDF]